Clinical Study of WT2725 in Patients With Advanced Malignancies

Phase 1 Completed 64 enrolled Sumitomo Pharma America, Inc. Sumitomo Pharma Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1

Timeline

Start: 2012-07-31
Primary completion: 2017-05-17
Completion: 2017-05-17

Publications

Fu S, Piccioni DE, Liu H, Lukas RV, Kesari S, Aregawi D, Hong DS, Yamaguchi K, Whicher K, Zhang Y, Chen YL, Poola N, Eddy J, Blum D. A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Sci Rep. 2021 Nov 16;11(1):22355. doi: 10.1038/s41598-021-01707-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WT2725	Vaccine	0.3 mg	Other
Subject	WT2725	Vaccine	0.9 mg	Other
Subject	WT2725	Vaccine	3 mg	Other
Subject	WT2725	Vaccine	9 mg	Other
Subject	WT2725	Vaccine	18 mg	Other
Subject	WT2725	Vaccine	27 mg	Other

Clinical Study of WT2725 in Patients With Advanced Malignancies

Summary

Timeline

Publications

Drugs

Indications